Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B

NCT05962398 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT05962398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05962398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B
Lead sponsor
CSL Behring
Phase
Observational
Overall status
Enrolling by invitation
Start date
August 30, 2023
Completion date
March 23, 2035
Enrollment
56 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b